Anyone who's been pleasantly surprised that they can still ride a bike or swim laps after a long hiatus might surmise that ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

Collagen stimulation and firmness: By feeding fibroblast cells with amino acid building blocks, Revok50 helps stimulate new ...

Not all zombie skin cells are the same. New research reveals three unique subtypes with different roles in aging and disease, ...

Explore the real results, benefits, ingredients, side effects, and customer experiences behind this skin and gut health ...

Senescent skin cells, often referred to as zombie cells because they have outlived their usefulness without ever quite dying, have existed in the human body as a seeming paradox, causing inflammation ...

Senescent skin cells, often referred to as zombie cells because they have outlived their usefulness without ever quite dying, ...

Researchers have identified three subtypes of senescent skin cells with distinct shapes, biomarkers, and functions -- an advance that could equip scientists with the ability to target and kill the ...